Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

Also called NCT03429543

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03429543
  • EudraCT 2016-000669-21
Other papers using this trial's data
  • Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial The lancet. Diabetes & endocrinology, 2023-03 DOI, PubMed 36738751, PMC10851109 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, China, Colombia, Germany, Israel, Mexico, Puerto Rico, Russia, South Korea, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03429543. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2022-10-19 (actual). Results posted on 2024-02-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin
Intervention (Drug)
Insulin
Intervention (Drug)
Placebo
Intervention (Drug)
Linagliptin
Intervention (Drug)
Empagliflozin
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct03429543
Content hash
a610cbbaf48e90525c0ab70207d5acf9509817a0fdf7cafdd2ea24dac0a25ea8